公开(公告)号：US20190153386A1

公开(公告)日：2019-05-23

申请号：US15816982

申请日：2017-11-17

申请人： James R. Musick ,  Tiana Tonrey ,  Richard Dean

发明人： James R. Musick ,  Tiana Tonrey ,  Richard Dean

IPC分类号： C12N5/0797 ,  C12N5/0793 ,  C12N5/077 ,  C12N5/071 ,  A61K35/12

摘要： An isolated biological stem cell or a set of biological stem cells that include human mesenchymal stem cell line 120816CT, deposited under ATCC Accession number PTA-124321, and differentiated into at least one type of cell selected from the group: neural stem cells, nephron progenitor cells, cardiomyocytes, neurons, glial cells, and vascular endothelial cells. The neurons comprise cholinergic neurons or dopaminergic neurons. A method of treating at least one human physical condition is also disclosed. The method includes injecting a patient with stem cell line 120816 CT to treat osteoarthritis, tendonitis, herniated disc, ligament damage, acute and chronic kidney disease and injury, Parkinson's disease, traumatic brain injury, Alzheimer's disease, amyotrophic lateral sclerosis, spinal cord injury, other skeletal muscular disorders, Lupus erythematosus, multiple sclerosis, cardiovascular disease, Graft-versus host disease, liver dysfunction or diseases, Type 1 and Type 2 diabetes, myocardial ischemia, heart failure, coronary artery disease, and other disorders characterized by inflammation.

公开(公告)号：US06458593B1

公开(公告)日：2002-10-01

申请号：US09489085

申请日：2000-01-21

申请人： James R. Musick ,  John Charles Gill, IV ,  Bruce P. Burnett ,  Tammy E. Hedlund

发明人： James R. Musick ,  John Charles Gill, IV ,  Bruce P. Burnett ,  Tammy E. Hedlund

IPC分类号： C12N1564

CPC分类号： C12N5/0616 ,  C12N2500/25 ,  C12N2501/11 ,  C12N2501/16 ,  C12N2501/39 ,  C12N2501/392 ,  C12N2501/395 ,  C12N2509/00 ,  C12N2510/02 ,  C12N2510/04

摘要： The present invention relates to methods of immortalizing various primary cell cultures, including pituitary cells, neurons, beta islet cells, glial cells, corneal epithelial cells and follicular stellate cells. The primary cells are transfected with a vector containing an establishment oncogene, resulting in non-transformed immortalized cells. The primary cells and/or the subsequent immortalized cells are cultured in a defined media containing one or more environmental factor(s) that control the proliferation and/or differentiation of the cells.

摘要翻译： 本发明涉及永生化各种原代细胞培养物，包括垂体细胞，神经元，胰岛细胞，胶质细胞，角膜上皮细胞和滤泡星状细胞的方法。 用含有致癌基因的载体转染原代细胞，导致未转化的永生化细胞。 将原代细胞和/或随后的永生化细胞在含有一种或多种控制细胞增殖和/或分化的环境因子的限定培养基中培养。

公开(公告)号：US5990288A

公开(公告)日：1999-11-23

申请号：US75423

申请日：1998-05-08

申请人： James R. Musick ,  Erik Van Horn

发明人： James R. Musick ,  Erik Van Horn

IPC分类号： C07K14/59 ,  C07K3/18 ,  C07K3/20 ,  C07K3/28

CPC分类号： C07K14/59

摘要： The present invention provides a method for purifying follicle stimulating hormone (FSH) from biological samples, for example, from human pituitary glands or human postmenopausal urine, wherein the FSH is contaminated with other proteins, by use of dye-ligand affinity chromatography (DAC). This process may be used to generate affinity pure FSH suitable for therapeutic applications.

摘要翻译： 本发明提供了通过使用染料 - 配体亲和层析（DAC）从生物样品例如来自人垂体腺或人类绝经后尿中纯化促卵泡激素（FSH）的方法，其中FSH被其他蛋白质污染， 。 该方法可用于产生适用于治疗应用的亲和纯FSH。

公开(公告)号：US07527971B2

公开(公告)日：2009-05-05

申请号：US11256673

申请日：2005-10-20

申请人： James R. Musick

发明人： James R. Musick

IPC分类号： C12N5/00 ,  C12N5/08 ,  A01N63/00 ,  A01N65/00

CPC分类号： C12N5/0678 ,  A61K35/12 ,  C12N5/0676 ,  C12N2501/335

摘要： The present invention is directed to a new cell line, VIT4-G9, which has been deposited as ATCC Accession number PTA-8683.

摘要翻译： 本发明涉及以ATCC登录号PTA-8683保藏的新细胞系VIT4-G9。

公开(公告)号：US06414123B1

公开(公告)日：2002-07-02

申请号：US09442132

申请日：1999-11-16

申请人： James R. Musick ,  Erik Van Horn

发明人： James R. Musick ,  Erik Van Horn

IPC分类号： C07K318

CPC分类号： C07K14/59

摘要： The present invention provides a method for purifying follicle stimulating hormone (FSH) from biological samples, for example, from human pituitary glands or human postmenopausal urine, wherein the FSH is contaminated with other proteins, by use of dye-ligand affinity chromatography (DAC). Depending on the starting material used and the initial purity of FSH in the starting material, additional purification steps may be employed. These steps preferably involve the use of hydrophobic interaction chromatography. This process may be used to generate affinity pure FSH suitable for therapeutic applications. The methods of the invention provide high purity FSH with high overall yield. A further advantage is the ability to easily regenerate the chromatography media for re-use, thus providing added economy to the purification process.